Transvitreal optic neurotomy improves visual acuity in recent-onset NAION

Article

Transvitreal optic neurotomy (TON) improves the visual acuity and visual fields in patients with nonarteritic anterior ischemic optic neuropathy (NAION) of recent onset.

Transvitreal optic neurotomy (TON) improves the visual acuity and visual fields in patients with nonarteritic anterior ischemic optic neuropathy (NAION) of recent onset, reported Gholam Peyman, MD, at the American Academy of Ophthalmology annual meeting.

Sixteen patients were included in this masked clinical trial. Eight patients were randomized to undergo TON and eight to observation. The TON procedure included pars plana vitrectomy. An MVR blade was used to cut through the pars plana and the margin of the optic nerve was incised. Patients were examined at 1, 3, 7, and 28 days and then monthly to 6 months postoperatively, Dr. Peyman explained. He is from the Tulane Health Science Center, New Orleans.

The results showed that in the patients who underwent TON, the best-corrected visual acuity was 2.03±0.9 compared with 1.1±0.37 for the control patients. The mean visual acuity improvement was greater in the surgical group than in the controls at 3 (0.8±0.49 compared with 0.24±0.45, respectively; p=0.03) and 6 (1.04±0.83 compared with 0.24±0.45, respectively; p=0.03) months postoperatively. Seventy-five percent of the surgical patients had an increase in visual acuity compared with 25% of controls (p=0.04). The visual fields improved significantly (p=0.01) in 75% of the surgical patients.

"TON may play a role in the treatment of NAION," Dr. Peyman concluded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
Related Content
© 2025 MJH Life Sciences

All rights reserved.